Navigation Links
Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

The BiovaxID Phase 3 clinical trial is being conducted at fourteen U.S. oncology centers and 8 centers in Russia.

Applications for accelerated conditional approval of BiovaxID are planned to be submitted to both the Food and Drug Administration (FDA) and European Medicines Agency (EMEA) by mid-2008. The DMC has agreed to serve as a liaison between the Company and the FDA and the EMEA. If conditionally approved, BiovaxID could become commercially available in early 2009.

Members of the investment community, the media, and other interested parties can access the PowerPoint presentation and an audio webcast by visiting Accentia's homepage at www.accentia.net, or for audio only, http://www.wsw.com/webcast/jeff18/abpi. The PowerPoint presentation and audio will be available and archived on Accentia's website for 90 days.

About Biovest International, Inc.

Biovest International, Inc., is a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. Biovest is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., (NASDAQ:ABPI) with its remaining shares publicly traded. Biovest has a foundation in the manufacture of biologics for research and clinical trials. In addition, Biovest develops, manufactures and markets patented cell culture systems, including the innovative AutovaxID(TM), which is being marketed as an automated vaccine manufacturing instrument and for production of cell-based materials and therapeutics. Biovest is currently conducting a pivotal Phase 3 clinical trial for BiovaxID which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID has been granted Fast Track status by the FDA. For further information, visit the Company Web site at www.biovest.com.

About Accentia Biopharmaceuticals, Inc.

Accentia Biopharmaceuticals, Inc. and its subsidiaries (collectively referred to as the "Company"
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
2. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
3. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
4. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
5. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
6. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
7. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New Treatment Benchmark in Patients With Metastatic Colorectal Cancer
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action
Post Your Comments:
(Date:1/23/2015)... Inc. (ICBU) has repositioned itself as a holding company with ... in the hydroponic, hemp and medical marijuana sectors. By acquiring ... sector, and recently partnering with the Chippewa Tribe Nation to ... iMD is committing to bring its vision to the market ...
(Date:1/23/2015)... Jan. 23, 2015  Mallinckrodt plc (NYSE: MNK ... approved a share repurchase program. The open-ended authorization permits ... Mallinckrodt plc ordinary shares. "Funding additional ... priorities as we continue to pursue a range of ...
(Date:1/22/2015)... , Jan. 22, 2015  BiOptix is pleased to announce ... Vice President of Chemistry and Biochemistry. Scott joins the company ... Pharmaceuticals, and Amgen throughout the course of his nearly ... "Scott is a nationally recognized thought leader in ...
Breaking Medicine Technology:iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... Require Further Investigations," Says ... Dissenting Panel Member, ... (CDC),study on the relationship between mercury (thimerosal) in vaccines and,children,s ... external consultants, Sallie Bernard, Executive Director of,SafeMinds. "Early Thimerosal ...
... Rapid-Acting, Non-Invasive Nasal Spray Dosage form is Patient Friendly ... Concerns of Pulmonary Delivery -, BOTHELL, Wash., Sept. ... announced today the start of a,Phase 2 clinical trial ... patients with type 2 diabetes. The study is a,randomized, ...
Cached Medicine Technology:Vaccine Study in New England Journal of Medicine Wrong in Concluding Mercury Exposures are Harmless, States SafeMinds 2Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for Insulin Nasal Spray to Treat Diabetes 2Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for Insulin Nasal Spray to Treat Diabetes 3
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, ... dresses. View website of AngelWeddingDress.com to find ... wedding dresses online for a bridal party. AngelWeddingDress offers ... for them. Its maternity wedding dresses are specially designed ...
(Date:1/22/2015)... released a new blog post explaining the main features of ... Auto insurance quotes help many drivers find the best coverage ... an agent or visit an agency for price information. These ... http://autocarinsurancebest.com/ . , Every business who relies heavily on transportation ...
(Date:1/22/2015)... 2015 Yesterday, Senator Holly Mitchell ... Kristin Olsen (R-Modesto) were honored by the California ... biotechnology, biomedical science, medical device and pharmaceutical innovation ... the “2014 Life Sciences Champion” award from CHI ...
(Date:1/22/2015)... 22, 2015 EBSCO Information Services ... expanding their relationship in an effort to further promote visibility ... While EBSCO has long made AMA journals available via its ... for The JAMA Network. , Long known as ...
(Date:1/22/2015)... Step into a macabre world where ... of Virginia. Wicked Plants, the Museum’s latest featured exhibition, ... poisonous, carnivorous and diabolical plants inside of a dilapidated, ... the biochemical, physical and neurological processes between botanicals and ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... with multiple medical problems, keeping up with countless doctor,s appointments, ... especially for those in challenging socioeconomic situations. ... emergency room, the country,s most expensive form of care delivery, ... a growing concept in health care reform called the "medical ...
... staying in the work force, but increasingly in part-time rather than full-time jobs, according to new research released today by the nonpartisan Employee Benefit Research Institute (EBRI). , ... , ... ... ...
... , TUESDAY, March 16 (HealthDay News) -- A carefully ... lung tumors stable in patients who had inoperable cancers. ... therapy, called stereotactic body radiation therapy (SBRT), were still ... findings from a study published in the March 17 ...
... Highly-focused stereotactic body radiation therapy (SBRT) can ... and may ultimately improve survival for patients with ... findings of a Radiation Therapy Oncology Group study ... the Journal of the American Medical Association ...
... a one-day workshop about the basics of technology entrepreneurship ... to launch a startup venture. Presentations will ... property issues and business plans. Participants include Erica Fuchs, ... Carnegie Mellon whose research focuses on the role of ...
... , ,New Rochelle, NY, March 16, 2010Announcing the ... dynamic new application delivering the latest news, resources, ... your iPhone. Convenient access to information across the ... environmental, and public health fields is available with ...
Cached Medicine News:Health News:Novel 'medical home' program for pediatric patients, families cuts ER visits in half 2Health News:Novel 'medical home' program for pediatric patients, families cuts ER visits in half 3Health News:New Research from EBRI: Older Workers Trending Toward More Part-Time Work 2Health News:New Research from EBRI: Older Workers Trending Toward More Part-Time Work 3Health News:Radiation May Help Those With Inoperable Lung Tumors 2Health News:Radiation May Help Those With Inoperable Lung Tumors 3Health News:SBRT eliminates tumors with promising survival for early-stage inoperable lung cancer patients 2Health News:SBRT eliminates tumors with promising survival for early-stage inoperable lung cancer patients 3
... 350 Liters of pure water, Complete, Compact ... Purified Water,Millipores compact S.D.S. Storage and Distribution ... 350 liters of purified water produced by ... consistent purity of stored water, provide effective ...
... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... has developed a range of Milli-Q ... specific water quality requirements. Each of ... designed to specifically target contaminants detrimental ... molecular biology and ICP-MS. The systems ...
Medicine Products: